麻醉药物导致的不同镇静状态对大脑功能影响的观察研究

注册号:

Registration number:

ChiCTR2400087009 

最近更新日期:

Date of Last Refreshed on:

2024-07-17 14:12:38 

注册时间:

Date of Registration:

2024-07-17 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

麻醉药物导致的不同镇静状态对大脑功能影响的观察研究

Public title:

The effects of different sedative states caused by anesthetics on brain function: An observational study

注册题目简写:

麻醉药物对大脑功能的影响

English Acronym:

Effects of anesthetics on brain function

研究课题的正式科学名称:

麻醉药物导致的不同镇静状态对大脑功能影响的观察研究

Scientific title:

The effects of different sedative states caused by anesthetics on brain function: An observational study

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

汤奕洁 

研究负责人:

吴晓丹 

Applicant:

YijieTang 

Study leader:

Xiaodan Wu 

申请注册联系人电话:

Applicant telephone:

+86 136 0699 7977

研究负责人电话:

Study leader's
telephone:

+86 130 5529 1720

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

358474705@qq.com

研究负责人电子邮件:

Study leader's E-mail:

wxiaodan@sina.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

福建省福州市仓山区金榕南路156号

研究负责人通讯地址:

福建省福州市仓山区金榕南路156号

Applicant address:

156 Jinrong South Road, Cangshan District, Fuzhou City, Fujian Province

Study leader's address:

156 Jinrong South Road, Cangshan District, Fuzhou City, Fujian Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

福建省立医院

Applicant's institution:

Fujian Provincial Hospital

研究负责人所在单位:

福建省立医院

Affiliation of the Leader:

Fujian Provincial Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

伦审科研第(K2024-06-056)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

福建省立医院伦理委员会

Name of the ethic committee:

Ethics Committee of Fujian Provincial Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2024-06-25 00:00:00

伦理委员会联系人:

练发杨

Contact Name of the ethic committee:

Fayang Lian

伦理委员会联系地址:

福建省福州市鼓楼区东街134号

Contact Address of the ethic committee:

134 East Street, Gulou District, Fuzhou City, Fujian Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 591 8821 6023

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

福建省立医院

Primary sponsor:

Fujian Provincial Hospital

研究实施负责(组长)单位地址:

福建省福州市鼓楼区东街134号

Primary sponsor's address:

134 East Street, Gulou District, Fuzhou City, Fujian Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

福建

市(区县):

福州

Country:

China

Province:

Fujian

City:

Fuzhou

单位(医院):

福建省立医院

具体地址:

福建省福州市鼓楼区东街134号

Institution
hospital:

Fujian Provincial Hospital

Address:

134 East Street, Gulou District, Fuzhou City, Fujian Province

经费或物资来源:

国家自然科学基金

Source(s) of funding:

National Natural Science Foundation of China

研究疾病:

麻醉对脑功能的影响  

Target disease:

Effects of anesthetics on brain function

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

单臂 

Study design:

Single arm 

研究目的:

主要目的:探究麻醉药物导致的不同镇静状态对大脑功能的影响差异 次要目的: 探究不同镇静状态下大脑功能的差异是否与围术期认知功能的改变相关联,从而为临床麻醉实践提供更多的神经生理学依据。  

Objectives of Study:

Main objective: To explore the effects of different sedative states caused by anesthetics on brain function. Secondary objective: To explore whether the differences in brain function under different sedation states are related to the changes in perioperative cognitive function, so as to provide more neurophysiological basis for clinical anesthesia practice.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

(1)有神经系统或心肺疾病; (2)打鼾; (3)阻塞性睡眠呼吸暂停综合症; (4)存在幽闭恐惧症等磁共振扫描禁忌症; (5)听力损失; (6)过敏史; (7)存在语言障碍者; (8)存在认知障碍者; (9)体内有金属植入物; (10)6个月内使用过麻醉剂者; (11)有药物滥用或酗酒史; (12)怀孕或哺乳期女性; (13)研究者认为不适宜参加。

Exclusion criteria:

(1) nervous system or cardiopulmonary diseases; (2) snoring; (3) obstructive sleep apnea syndrome; (4) claustrophobia and other contraindications to MRI scanning; (5) hearing loss; (6) history of allergy; (7) those with language disorders; (8) with cognitive impairment; (9) metallic implants in the body; (10) using anesthetics within 6 months; (11) having a history of drug abuse or alcohol abuse; (12) pregnant or lactating women; (13) The investigator considered it inappropriate to participate.

研究实施时间:

Study execute time:

From 2024-07-20 00:00:00 To 2025-01-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-07-20 00:00:00 To 2025-01-31 00:00:00

干预措施:

Interventions:

组别:

丙泊酚麻醉组

样本量:

20

Group:

Propofol anesthesia group

Sample size:

干预措施:

给予丙泊酚麻醉前进行静息态功能磁共振扫描。开始给予丙泊酚,并持续监测被试的生理指标,确保其在整个扫描过程中处于轻/中度镇静状态,并进行静息态功能磁共振扫描。轻/中度麻醉维持阶段结束之后,增加麻醉剂量,并持续监测被试的生理指标,确保其在整个扫描过程中处于重度镇静状态,并进行静息态功能磁共振扫描。

干预措施代码:

Intervention:

A resting fMRI scan was performed before propofol anesthesia. Propofol was administered and physiological indicators were continuously monitored to ensure light/moderate sedation throughout the scan, as well as resting-state FMRI scans. After the end of the light/moderate anesthesia maintenance phase, the anesthetic dose was increased, and the

Intervention code:

组别:

右美托咪定麻醉组

样本量:

10

Group:

Dexmedetomidine anesthesia group

Sample size:

干预措施:

给予右美托咪啶麻醉前进行静息态功能磁共振扫描。开始给予右美托嘧啶,并持续监测被试的生理指标,确保其在整个扫描过程中处于轻/中度镇静状态,并进行静息态功能磁共振扫描。轻/中度麻醉维持阶段结束之后,增加麻醉剂量,并持续监测被试的生理指标,确保其在整个扫描过程中处于重度镇静状态,并进行静息态功能磁共振扫描。

干预措施代码:

Intervention:

Give the right supporting pyrimidine resting state fmri scans were taken before the anesthesia. Dexmedetomidine administration was started, and the physiological parameters of the subjects were continuously monitored to ensure that they were mildly/moderately sedating throughout the scanning process, and a resting-state functional magnetic resonance scan was performed. After the maintenance phase of mild/moderate anesthesia, the anesthetic dose was increased, and the physiological indicators of the subjects were continuously monitored to ensure that they were in a severe state of sedation during the whole scanning process, and a resting-state functional magnetic resonance imaging scan was performed.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

福建 

市(区县):

福州 

Country:

China

Province:

Fujian

City:

Fuzhou

单位(医院):

福建省立医院 

单位级别:

三甲 

Institution
hospital:

Fujian Provincial Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

大脑功能状态

指标类型:

主要指标

Outcome:

Brain functional status

Type:

Primary indicator

测量时间点:

测量方法:

静息态功能磁共振

Measure time point of outcome:

Measure method:

Resting state functional magnetic resonance

指标中文名:

认知功能

指标类型:

次要指标

Outcome:

cognitive function

Type:

Secondary indicator

测量时间点:

测量方法:

量表

Measure time point of outcome:

Measure method:

指标中文名:

生命体征监测指标

指标类型:

附加指标

Outcome:

Vital signs monitoring indicators

Type:

Additional indicator

测量时间点:

测量方法:

心电监护

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 40 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不共享原始数据

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Raw data are not shared

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

通过病历记录表采集数据,后将数据内容输入至ResMan临床试验公共管理平台

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data will be collected through case record form and entered into the ResMan clinical trial public management platform

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2024-07-17 14:12:19